Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: R. M. Rosenthal who wrote (5591)	10/17/1999 8:37:00 PM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 5736

Read these numbers from the CCSI conference call in September to better understand what a large market that CCSI and Datex-Ohmeda are beginning to address. The Company believes that published amounts for the current reimbursement by third party carriers for heelstick bilirubin tests, not part of a general panel, range between $22-$34 per test in the United States. Assuming a $22 fee, the Company estimates a current annual amount spent on monitoring bilirubin jaundice in the U.S. of $330,000,000. The first 300 Colormate® Tlc-BiliTest® System units and 130,000 Tlc-Lensette(TM) are out the door. More will be shipped soon in my opinion! Thanks, Jeff